Navigation Links
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:6/4/2010

CHICAGO, June 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the first results from its collaboration with Pfizer Oncology to study early-stage renal cell carcinoma prognosis, which demonstrated a strong correlation between gene expression and recurrence risk in this patient population.  The study, which will be presented in an oral presentation tomorrow (8 – 9:30 a.m. CT) at the ASCO annual meeting in Chicago, could lead to the development of a multi-gene diagnostic test that estimates the risk of recurrence following surgery and that may ultimately aid in the subsequent identification of early-stage patients with renal cell carcinoma who could benefit most from treatment.

"Many early-stage renal cell carcinoma patients experience a recurrence of their cancer, yet there is currently no accurate means to identify the most aggressive cancers in advance," said Brian Rini, M.D., staff oncologist at Cleveland Clinic Taussig Cancer Institute and principle investigator on the study (i). "The strong correlation between gene expression and recurrence risk demonstrated in this study could help select the appropriate renal cell carcinoma patients for future drug development trials and potentially identify patients most likely to benefit from adjuvant therapy following surgery."

The study, "Identification of Prognostic Genomic Markers in Patients with Localized Clear Cell Renal Cell Carcinoma" (Abstract 4501), is the largest genomic analysis of localized clear cell renal carcinoma performed to date.  Additionally, it represents the first publicly presented results of Genomic Health's collaboration with Pfizer Oncology for assessing prognosis in patients with stage 1-3 renal carcinoma, clear cell type, that has not spread to other parts of the body.

Researchers evaluated more than 700 candidate genes from 942 stage 1-3 clear cell renal carcinoma patients treated at Cleveland Clinic between 1985 and 2003.  Genomic factors strongly associated with risk of recurrence and clinical/pathologic covariates were identified.  The magnitude of hazard ratios was comparable to those of other clinically used prognostic markers, such as estrogen-receptor status and HER2 status in breast cancer.  Researchers suggest that these results could be used to create a multi-gene algorithm to predict recurrence of early-stage renal cell carcinoma.

"Genomic Health's collaboration with Pfizer represents an industry-leading example of academic, diagnostic and therapeutic organizations combining resources and areas of expertise in order to advance the field of personalized medicine," said Steven Shak, M.D., chief medical officer, Genomic Health.  "Similar to what Genomic Health found using its quantitative RT-PCR technology in breast and colon cancers, this study shows that renal carcinoma tumors are not all the same and we believe this finding has the potential to provide critical insight for determining how early-stage renal cell carcinoma is treated in the future."  

The clear cell type of renal carcinoma is the most common type of kidney cancer in adults, affecting an estimated 25,000 people each year in the United States, and the incidence of the disease may be increasing.  As part of the collaboration, Genomic Health and Pfizer applied the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX® breast and colon cancer tests.

"We have the potential to individualize the treatment of early-stage renal cell carcinoma by assessing the risk of recurrence more accurately," said Isan Chen, M.D., Vice President - Genitourinary Tumor Strategy Team Leader, Pfizer Oncology Business Unit. "With a growing portfolio of kidney cancer therapies, Pfizer is committed to advancing the science and management of this disease.  Together with Genomic Health we intend to continue to define the clinical strategy and next steps for our work in renal cell carcinoma."

(i) Dr. Rini is also a member of the Pfizer scientific advisory board.  

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of March 31, 2010, more than 10,000 physicians in over 55 countries had ordered more than 148,000 Oncotype DX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the study data could lead to the development of a multi-gene diagnostic test to estimate the recurrence risk in  renal cell carcinoma patients and possibly aid in the identification of patients who could most benefit from adjuvant  treatment, the belief that its collaboration with Pfizer represents an industry-leading example of combining resources and expertise to advance the field of personalized medicine, the belief that our prior development and commercialization strategy can be applied to renal cell carcinoma, our expectations regarding the size of the potential market, the continuation and success of our collaboration with Pfizer, and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of the collaborative arrangement; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
2. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
3. Genomic Health to Announce First Quarter 2010 Financial Results and Host Conference Call on Wednesday, May 5, 2010
4. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
5. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
6. Transgenomic Reports Fourth Quarter Financial Results
7. AutoGenomics Announces the Launch of a Novel Test for B-RAF Mutations
8. NeoGenomics Schedules Its Q4 and Full Year 2009 Earnings Release for February 25, 2010
9. AutoGenomics Receives ISO Certification
10. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
11. Genomic Health Announces Year-End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):